2003～2013年北京市普伐他汀不良反应分析

Adverse drug reactions analysis on pravastatin in Beijing during 2003-2013

目的 2013版ACC/AHA成人降胆固醇指南中将普伐他汀归类为中效的降脂药,但因其不同于其他他汀类药物的代谢途径而被广泛使用,本文对其安全性进行评价。方法调取北京市不良反应监测中心建立以来该品种的不良反应报告资料,进行回顾性系统分析。结果肝损害和皮疹等可能是普伐他汀的主要不良反应,并未发现横纹肌溶解的报告。结论普伐他汀在治疗剂量下是安全有效的降脂药。

Objective Pravastatin has been defined as a moderate-intensity statinin.Because of its different metabolic pathways from other statins,it is necessary to evaluate its safety.Methods The ADR reports from the Adverse Reaction Monitoring Center in Beijing were analyzed from the beginning.Results The liver damage and skin rash is the main ADRs of pravastatin,there was no rhabdomyolysis report.Conclusion Pravastatin is safe and effective in nomal dose.